These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26433692)

  • 41. Studies on the biosynthesis and morphogenesis of R-type pyocins of Pseudomonas aeruginosa. IV. Quantitative estimation of the rates of synthesis of pyocin R subunit proteins.
    Shinomiya T
    J Biochem; 1974 Nov; 76(5):1083-94. PubMed ID: 4217793
    [No Abstract]   [Full Text] [Related]  

  • 42. Bactericidal activity of the tail of Pseudomonas aeruginosa bacteriophage PS17.
    Shinomiya T; Shiga S
    J Virol; 1979 Dec; 32(3):958-67. PubMed ID: 117121
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Variation in phage typing and pyocin typing of Pseudomonas aeruginosa].
    Polanec-Cernosa J; Dragas AZ; Janc M
    Vojnosanit Pregl; 1989; 46(1):36-7. PubMed ID: 2499115
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phage tail-like bacteriocin suppresses competitors in metapopulations of pathogenic bacteria.
    Backman T; Latorre SM; Symeonidi E; Muszyński A; Bleak E; Eads L; Martinez-Koury PI; Som S; Hawks A; Gloss AD; Belnap DM; Manuel AM; Deutschbauer AM; Bergelson J; Azadi P; Burbano HA; Karasov TL
    Science; 2024 Jun; 384(6701):eado0713. PubMed ID: 38870284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Pseudomonas pyocin typing method applicable to the clinical laboratory.
    Barnes WG; Gitta PS
    Am J Med Technol; 1979 Aug; 45(8):688-91. PubMed ID: 114048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strategies for developing phages into novel antimicrobial tailocins.
    Woudstra C; Sørensen AN; Sørensen MCH; Brøndsted L
    Trends Microbiol; 2024 Apr; ():. PubMed ID: 38580606
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Live cell dynamics of production, explosive release and killing activity of phage tail-like weapons for Pseudomonas kin exclusion.
    Vacheron J; Heiman CM; Keel C
    Commun Biol; 2021 Jan; 4(1):87. PubMed ID: 33469108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phagovar determination of Pseudomonas aeruginosa and a comparison of the results with mitomycin C induced pyocin production.
    Sticht-Groh V
    Zentralbl Bakteriol A; 1981; 249(2):225-34. PubMed ID: 6791406
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Level of resistance of clinical isolates of Pseudomonas aeruginosa as related to their susceptibility to phages and R-pyocins.
    Legakis N; Koukoubanis N; Malliara K; Tumah H
    Chemioterapia; 1987 Jun; 6(2 Suppl):200-1. PubMed ID: 3151342
    [No Abstract]   [Full Text] [Related]  

  • 50. Biophysicochemical characterization of Pyocin SA189 produced by Pseudomonas aeruginosa SA189.
    Naz SA; Jabeen N; Sohail M; Rasool SA
    Braz J Microbiol; 2015; 46(4):1147-54. PubMed ID: 26691474
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [TL, the new bacteriophage of Pseudomonas aeruginosa and its application for the search of halo-producing bacteriophages].
    Pleteneva EA; Burkal'tseva MV; Shaburova OV; Krylov SV; Pechnikova EV; Sokolova OS; Krylov VN
    Genetika; 2011 Jan; 47(1):5-9. PubMed ID: 21446178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preferential inhibition of lipid synthesis by the bacteriocin pyocin S2.
    Okawa I; Maruo B; Kageyama M
    J Biochem; 1975 Jul; 78(1):213-23. PubMed ID: 811653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A predicted immunity protein confers resistance to pyocin S5 in a sensitive strain of Pseudomonas aeruginosa.
    Rasouliha BH; Ling H; Ho CL; Chang MW
    Chembiochem; 2013 Dec; 14(18):2444-6. PubMed ID: 24222552
    [No Abstract]   [Full Text] [Related]  

  • 54. The role of 'soaking' in spiteful toxin production in Pseudomonas aeruginosa.
    Inglis RF; Hall AR; Buckling A
    Biol Lett; 2013 Feb; 9(1):20120569. PubMed ID: 22933037
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa.
    Wang J; Hu B; Xu M; Yan Q; Liu S; Zhu X; Sun Z; Reed E; Ding L; Gong J; Li QQ; Hu J
    Int J Mol Med; 2006 Feb; 17(2):309-17. PubMed ID: 16391831
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ciprofloxacin induction of a susceptibility determinant in Pseudomonas aeruginosa.
    Brazas MD; Hancock RE
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3222-7. PubMed ID: 16048929
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Global Transcriptomic Analysis of Interactions between Pseudomonas aeruginosa and Bacteriophage PaP3.
    Zhao X; Chen C; Shen W; Huang G; Le S; Lu S; Li M; Zhao Y; Wang J; Rao X; Li G; Shen M; Guo K; Yang Y; Tan Y; Hu F
    Sci Rep; 2016 Jan; 6():19237. PubMed ID: 26750429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation of pyocyanine & pyocin production by clinical isolates of Pseudomonas aeruginosa.
    Subramaniam L; Shriniwas
    Indian J Med Res; 1986 Sep; 84():255-9. PubMed ID: 3102362
    [No Abstract]   [Full Text] [Related]  

  • 59. [Bacteriophage phi297--the new species of temperate phages Pseudomonas aeruginosa with a mosaic genome: potential use in phagotherapy].
    Burkal'tseva MV; Krylov SV; Kropinskiĭ AM; Pletneva EA; Shaburova OV; Krylov VN
    Genetika; 2011 Jul; 47(7):900-4. PubMed ID: 21938953
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bacteriophage can lyse antibiotic-resistant Pseudomonas aeruginosa isolated from canine diseases.
    Furusawa T; Iwano H; Higuchi H; Yokota H; Usui M; Iwasaki T; Tamura Y
    J Vet Med Sci; 2016 Jul; 78(6):1035-8. PubMed ID: 26876365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.